Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study

Abstract

Background Plasmodium vivax exacts a significant toll on health worldwide, yet few efforts to date have quantified the extent and temporal trends of its global distribution. Given the challenges associated with the proper diagnosis and treatment of P vivax, national malaria programmes-particularly those pursuing malaria elimination strategiesrequire up to date assessments of P vivax endemicity and disease impact. This study presents the first global maps of P vivax clinical burden from 2000 to 2017. Methods In this spatial and temporal modelling study, we adjusted routine malariometric surveillance data for known biases and used socioeconomic indicators to generate time series of the clinical burden of P vivax. These data informed Bayesian geospatial models, which produced fine-scale predictions of P vivax clinical incidence and infection prevalence over time. Within sub-Saharan Africa, where routine surveillance for P vivax is not standard practice, we combined predicted surfaces of Plasmodium falciparum with country-specific ratios of P vivax to P falciparum. These results were combined with surveillance-based outputs outside of Africa to generate global maps. Findings We present the first high-resolution maps of P vivax burden. These results are combined with those for P falciparum (published separately) to form the malaria estimates for the Global Burden of Disease 2017 study. The burden of P vivax malaria decreased by 41•6%, from 24•5 million cases (95% uncertainty interval 22•5-27•0) in 2000 to 14•3 million cases (13•7-15•0) in 2017. The Americas had a reduction of 56•8% (47•6-67•0) in total cases since 2000, while SouthEast Asia recorded declines of 50•5% (50•3-50•6) and the Western Pacific regions recorded declines of 51•3% (48•0-55•4). Europe achieved zero P vivax cases during the study period. Nonetheless, rates of decline have stalled in the past five years for many countries, with particular increases noted in regions affected by political and economic instability. Interpretation Our study highlights important spatial and temporal patterns in the clinical burden and prevalence of P vivax. Amid substantial progress worldwide, plateauing gains and areas of increased burden signal the potential for challenges that are greater than expected on the road to malaria elimination. These results support global monitoring systems and can inform the optimisation of diagnosis and treatment where P vivax has most impact. Funding Bill & Melinda Gates Foundation and the Wellcome Trust.

New malaria maps

“…Exposure to broad-spectrum antibiotics alters the body's microbiota, increases opportunistic infections, and promotes antimicrobial resistance (AMR), which may restrict future treatment options for the child. 1 Therefore, a contextual evaluation of risks and benefits is necessary when prescribing antibiotics.…”

Reticulocyte Infection Leads to Altered Behaviour, Drug Sensitivity and Host Cell Remodelling byPlasmodium falciparum

“…P. falciparum and P. vivax present contrasting cases in terms of distribution, disease severity 53 , drug sensitivity/resistance 54 and relapse 55 . Perhaps, the most intriguing aspect that differentiates these two species is the strict restriction of P. vivax to immature reticulocytes 11 .…”

Mapping malaria seasonality in Madagascar using health facility data

“…One benefit of using S j is that it separates the timing and amplitude aspects of seasonality. Since high-resolution malaria burden estimates already exist [26][27][28], the model did not need to estimate the number of cases and could focus exclusively on estimating the monthly proportions at each location. Estimates of the monthly parasite incidence (MPI) for each location could also be obtained by multiplying the estimated monthly proportions with the mean Pf API estimates for 2016.…”